BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36892747)

  • 1. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
    Feng W; He Z; Shi L; Zhu Z; Ma H
    Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
    Li F; Niu Y; Zhao W; Yan C; Qi Y
    Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    Zhang H; Lin J; Yahaya BH
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma.
    Liu Y; Lin W; Qian H; Yang Y; Zhou X; Wu C; Pan X; Liu Y; Wang G
    BMC Med Genomics; 2024 Jan; 17(1):12. PubMed ID: 38167084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of HSF2BP in lung adenocarcinoma.
    Huang Z; Liu Z; Cheng X; Han Z; Li J; Xia T; Gao Y; Wei L
    Ann Transl Med; 2021 Oct; 9(20):1559. PubMed ID: 34790765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
    Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
    Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
    Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L
    J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
    Huang D; Tang E; Zhang T; Xu G
    Front Immunol; 2022; 13():916284. PubMed ID: 35860256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
    Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene expression-based immune signature for lung adenocarcinoma prognosis.
    Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
    Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
    Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
    Front Immunol; 2022; 13():992626. PubMed ID: 36311724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
    Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
    BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.